Watt F, Watanabe R, Yang W, Agren N, Arvidsson Y, Funa K
Children's Cancer Institute Australia for Medical Research, Randwick, New South Wales, Australia.
Cancer Gene Ther. 2007 Mar;14(3):287-96. doi: 10.1038/sj.cgt.7701012. Epub 2006 Nov 24.
Neuroblastoma is one of the most common solid tumors in childhood. With the aim of developing a targeting vector for neuroblastoma, we cloned and characterized an enhancer in the 5'-flanking regions of the MASH1 gene by a random-trap method from a 36 kb cosmid DNA. The enhancer-containing clone was identified by the expression of GFP when transfected into neuroblastoma cell lines. The enhancer-luciferase activity is higher in neuroblastoma cell lines, IMR32, BE2 and SH-SY5Y, compared with those in non-neuroblastoma cell lines, U1242 glioma, N417 small cell lung cancer and EOMA hemangioma. The core enhancer was determined within a 0.2 kb fragment, yielding three- to fourfold higher activity than that of the MASH1 promoter alone in IMR32 and BE2. This area possesses GATA- and CREB-binding sites, as well as the E-box. EMSA on this area demonstrated that CREB/ATF could bind the DNA. Chromatin immunoprecipitation assay revealed that N-myc, CREB, and co-activators CBP and PCAF, but not HDAC1, are bound to the core enhancer at the same time as the co-activators and N-myc bind to the promoter. This supports the idea that the commonly overexpressed genes HASH1 and N-myc are regulated in concert, confirming their importance as prognostic markers or targets for therapy.
神经母细胞瘤是儿童期最常见的实体瘤之一。为了开发一种针对神经母细胞瘤的靶向载体,我们通过随机捕获法从一个36 kb的黏粒DNA中克隆并鉴定了MASH1基因5'侧翼区域的一个增强子。当转染到神经母细胞瘤细胞系中时,通过绿色荧光蛋白(GFP)的表达鉴定出含增强子的克隆。与非神经母细胞瘤细胞系U1242胶质瘤、N417小细胞肺癌和EOMA血管瘤相比,神经母细胞瘤细胞系IMR32、BE2和SH-SY5Y中的增强子-荧光素酶活性更高。核心增强子定位于一个0.2 kb的片段内,在IMR32和BE2中其活性比单独的MASH1启动子高3至4倍。该区域具有GATA和CREB结合位点以及E盒。该区域的电泳迁移率变动分析(EMSA)表明CREB/ATF能够结合DNA。染色质免疫沉淀分析显示,N-myc、CREB以及共激活因子CBP和PCAF与核心增强子结合,而HDAC1不结合,同时共激活因子和N-myc与启动子结合。这支持了普遍过度表达的基因HASH1和N-myc协同调控的观点,证实了它们作为预后标志物或治疗靶点的重要性。